

**The NCCN**

# Antiemesis

## Clinical Practice Guidelines in Oncology™

David S. Ettinger, MD; Debra K. Armstrong, RN; Sally Barbour, PharmD, BCOP; Michael J. Berger, PharmD, BCOP; Philip J. Bierman, MD; Bob Bradbury, BCPS; Georgianna Ellis, MD; Steve Kirkegaard, PharmD; Dwight D. Kloth, PharmD, FCCP, BCOP; Mark G. Kris, MD; Dean Lim, MD; Michael Anne Markiewicz, PharmD; Lida Nabati, MD; Carli Nesheiwat, PharmD, BCOP; Hope S. Rugo, MD; Steven M. Sorscher, MD; Lisa Stucky-Marshall, RN, MS; Barbara Todaro, PharmD; and Susan Urba, MD

## Overview

Chemotherapy-induced vomiting (emesis) and nausea can significantly affect a patient's quality of life, leading to poor compliance with further chemotherapy treatment. Nausea and vomiting can also result in metabolic imbalances, degeneration of self-care and functional ability, nutrient depletion, anorexia, decline of performance and mental status, wound dehiscence, esophageal tears, and withdrawal from potentially useful or curative anticancer treatment.<sup>1-4</sup>

The incidence and severity of nausea and/or vomiting in patients undergoing chemotherapy are affected by numerous factors, including 1) the specific chemotherapeutic agents used, 2) dosage of the agents, 3) schedule and route of administration of the agents, and 4) individual patient variability (e.g.,

### Antiemesis Clinical Practice Guidelines in Oncology

#### Key Words

NCCN Clinical Practice Guidelines, antiemesis, nausea and vomiting, chemotherapy-induced, 5-HT<sub>3</sub>-receptor antagonists, NK-1-receptor antagonists (*JNCCN* 2009;7:572-595)

#### NCCN Categories of Evidence and Consensus

**Category 1:** The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.

**Category 2A:** The recommendation is based on lower-level evidence and there is uniform NCCN consensus.

**Category 2B:** The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).

**Category 3:** The recommendation is based on any level of evidence but reflects major disagreement.

All recommendations are category 2A unless otherwise noted.

**Clinical trials:** The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

#### Please Note

These guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.

These guidelines are copyrighted by the National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of the NCCN © 2009.

#### Disclosures for the NCCN Antiemesis Guidelines Panel

At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through 2008, this information was published in an aggregate statement in *JNCCN* and on-line. Furthering NCCN's commitment to public transparency, this disclosure process has now been expanded by listing all potential conflicts of interest respective to each individual expert panel member.

Individual disclosures for the NCCN Antiemesis Guidelines Panel members can be found on page 595. (To view the most recent version of these guidelines and accompanying disclosures, visit the NCCN Web site at [www.nccn.org](http://www.nccn.org).)

These guidelines are also available on the Internet. For the latest update, please visit [www.nccn.org](http://www.nccn.org).

age, sex, prior chemotherapy, history of alcohol use). Approximately 70% to 80% of all patients undergoing chemotherapy experience nausea and/or vomiting,<sup>5,6</sup> whereas 10% to 44% experience anticipatory nausea and/or vomiting;<sup>7-10</sup> patients often experience more nausea than vomiting.<sup>11</sup>

### Pathophysiology of Emesis

Vomiting results from stimulation of a multistep reflex pathway controlled by the brain, and is triggered by afferent impulses to the vomiting center (located in the medulla) from the chemoreceptor trigger zone; pharynx and gastrointestinal tract (by way of vagal afferent fibers); and cerebral cortex. Vomiting occurs when efferent impulses are sent from the vomiting

center to the salivation center, abdominal muscles, respiratory center, and cranial nerves.<sup>12</sup>

The chemoreceptor trigger zone, vomiting center, and gastrointestinal tract have many neurotransmitter receptors. Activation of these receptors by chemotherapeutic agents or their metabolites may be responsible for chemotherapy-induced emesis. Principal neuroreceptors involved in the emetic response are serotonin (5-hydroxytryptamine [5-HT<sub>3</sub>]) and dopamine receptors;<sup>13,14</sup> other neuroreceptors include acetylcholine, corticosteroid, histamine, cannabinoid, opiate, and neurokinin-1 (NK-1) receptors, which are located in the vomiting and vestibular centers of the brain.<sup>15</sup>

Antiemetic agents can block different neuronal pathways, exert their effects at different points dur-

Text continues on p. 585

### NCCN Antiemesis Panel Members

\*David S. Ettinger, MD/Chair†  
 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Debra K. Armstrong, RN#  
 Vanderbilt-Ingram Cancer Center

Sally Barbour, PharmD, BCOPΣ  
 Duke Comprehensive Cancer Center

Michael J. Berger, PharmD, BCOPΣ  
 The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

Philip J. Bierman, MD†‡  
 UNMC Eppley Cancer Center at The Nebraska Medical Center

Bob Bradbury, BCPSΣ  
 H. Lee Moffitt Cancer Center & Research Institute

Georgianna Ellis, MD†  
 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Steve Kirkegaard, PharmDΣ  
 Huntsman Cancer Institute at the University of Utah

\*Dwight D. Kloth, PharmD, FCCP, BCOPΣ  
 Fox Chase Cancer Center

\*Mark G. Kris, MD†  
 Memorial Sloan-Kettering Cancer Center

Dean Lim, MD†  
 City of Hope Comprehensive Cancer Center

Michael Anne Markiewicz, PharmDΣ  
 University of Alabama at Birmingham Comprehensive Cancer Center

Lida Nabati, MD£P  
 Dana-Farber/Brigham and Women's Cancer Center

Carli Nesheiwat, PharmD, BCOPΣ  
 St. Jude Children's Research Hospital/University of Tennessee Cancer Institute

Hope S. Rugo, MD†‡  
 UCSF Helen Diller Family Comprehensive Cancer Center

Steven M. Sorscher, MD†  
 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Lisa Stucky-Marshall, RN, MS#  
 Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Barbara Todaro, PharmDΣ  
 Roswell Park Cancer Institute

Susan Urba, MD†£  
 University of Michigan Comprehensive Cancer Center

#### KEY:

\*Writing Committee Member


Specialties: †Medical Oncology; #Nurse; ΣPharmacology; ‡Hematology/Hematology Oncology; £Supportive Care, Including Palliative, Pain Management, Pastoral Care, and Oncology Social Work; ¶Internal Medicine

## PRINCIPLES OF EMESIS CONTROL IN THE CANCER PATIENT

- Preventing nausea/vomiting is the goal.
  - ▶ The risk for nausea/vomiting in persons undergoing chemotherapy of high and moderate emetic risk lasts at least 4 days for high and 3 days for moderate. Patients must be protected throughout the full period of risk.
- Oral and IV antiemetic formulations have equivalent efficacy.
- Consider the toxicity of the specific antiemetic(s).
- Choice of antiemetic(s) used should be based on the emetic risk of the therapy, prior experience with antiemetics, and patient-specific factors.
- Other potential causes of emesis in cancer patients include:
  - ▶ Partial or complete bowel obstruction
  - ▶ Vestibular dysfunction
  - ▶ Brain metastases
  - ▶ Electrolyte imbalance: hypercalcemia, hyperglycemia, hyponatremia
  - ▶ Uremia
  - ▶ Concomitant drug treatments, including opiates
  - ▶ Gastroparesis: tumor- or chemotherapy- (e.g., vincristine) induced
  - ▶ Psychophysiological:
    - ◊ Anxiety
    - ◊ Anticipatory nausea and vomiting
- For use of antiemetics for nausea and vomiting that are not related to radiation and/or chemotherapy, see NCCN Clinical Practice Guidelines in Oncology: Palliative Care.\*
- For multidrug regimens, select antiemetic therapy based on drug with the highest emetic risk. See Emetogenic Potential of Antineoplastic Agents (page 580).
- Consider using an H<sub>2</sub> blocker or proton pump inhibitor to prevent dyspepsia, which can mimic nausea.

\*To view the most recent version of these guidelines, visit the NCCN Web site at [www.nccn.org](http://www.nccn.org).

## Antiemesis Version 3:2009

HIGH EMETIC RISK CHEMOTHERAPY - EMESIS PREVENTION<sup>b,c</sup>

See Principles of Emesis Control (opposite page)

<sup>a</sup>Data for post-cisplatin ( $\geq 50$  mg/m<sup>2</sup>) emesis prevention are category 1, others are category 2A.


<sup>b</sup>Antiemetic regimens should be chosen based on the drug with the highest emetic risk and on patient-specific risk factors.

<sup>c</sup>See Principles for Managing Multi-Day Emetogenic Chemotherapy Regimens (page 583).

<sup>d</sup>Fosaprepitant dimeglumine (115 mg) may be substituted for aprepitant (125 mg) 30 minutes before chemotherapy, on day 1 only of the chemotherapy-induced nausea and vomiting regimen as an infusion administered over 15 minutes.

<sup>e</sup>In a randomized study, a larger dose of palonosetron was used without aprepitant. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. *Lancet Oncol* 2009;10:115-124.

<sup>f</sup>Order of listed antiemetics does not reflect preference.

MODERATE EMETIC RISK CHEMOTHERAPY - EMESIS PREVENTION<sup>b,c</sup>

<sup>b</sup>Antiemetic regimens should be chosen based on the drug with the highest emetic risk and on patient-specific risk factors.

<sup>c</sup>See Principles for Managing Multi-Day Emetogenic Chemotherapy Regimens (page 583).

<sup>d</sup>Fosaprepitant dimeglumine (115 mg) may be substituted for aprepitant (125 mg) 30 minutes before chemotherapy, on day 1 only of the chemotherapy-induced nausea and vomiting regimen as an infusion administered over 15 minutes.

<sup>f</sup>Order of listed antiemetics does not reflect preference.



<sup>g</sup>Aprepitant should be added (to dexamethasone and a 5-HT<sub>3</sub> antagonist regimen) for select patients undergoing other chemotherapies of moderate emetic risk (e.g., carboplatin, cisplatin, doxorubicin, epirubicin, ifosfamide, irinotecan, methotrexate).

<sup>h</sup>Data for post-carboplatin ( $\geq 300$  mg/m<sup>2</sup>, cyclophosphamide  $\geq 600$ -1000 mg/m<sup>2</sup>, doxorubicin  $\geq 50$  mg/m<sup>2</sup>) emesis prevention are category 1.

Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise noted.

Antiemesis Version 3:2009

LOW AND MINIMAL EMETIC RISK CHEMOTHERAPY - EMESIS PREVENTION<sup>b,c</sup>




<sup>b</sup>Antiemetic regimens should be chosen based on the drug with the highest emetic risk and on patient-specific risk factors.  
<sup>c</sup>See Principles for Managing Multi-Day Emetogenic Chemotherapy Regimens (page 583).  
<sup>i</sup>Monitor for dystonic reactions; use diphenhydramine 25-50 mg PO or IV either every 4 or every 6 h for dystonic reactions.

BREAKTHROUGH TREATMENT FOR CHEMOTHERAPY INDUCED NAUSEA/VOMITING<sup>c,j</sup>No nausea/  
emesis

→ No change in antiemetic regimen

Any nausea/  
emesis →

- General principle of breakthrough treatment is to give an additional agent from a different drug class prn
  - ▶ Prochlorperazine 25 mg supp pr every 12 h or 10 mg PO or IV every 4 or 6 h<sup>i</sup>
  - or
  - ▶ Metoclopramide 10-40 mg PO or IV either every 4 or 6 h<sup>i</sup>
  - or
  - ▶ Lorazepam 0.5-2 mg PO either every 4 or 6 h
  - or
  - ▶ Dolasetron 100 mg PO daily or 1.8 mg/kg IV or 100 mg IV
  - or
  - ▶ Ondansetron 16 mg PO or 8 mg IV daily
  - or
  - ▶ Granisetron 1-2 mg PO daily or 1 mg PO bid or 0.01 mg/kg (maximum 1 mg) IV or transdermal patch containing 34.3 mg granisetron
  - or
  - ▶ Haloperidol 1-2 mg PO every 4-6 h prn
  - or
  - ▶ Dronabinol 5-10 mg PO either every 3 or 6 h
  - or
  - ▶ Nabilone 1-2 mg PO bid
  - or
  - ▶ Dexamethasone 12 mg PO or IV daily
  - or
  - ▶ Olanzapine 2.5-5 mg PO bid (category 2B)<sup>k</sup>
  - or
  - ▶ Promethazine 12.5-25 mg PO or IV every 4 h



<sup>c</sup>See Principles for Managing Multi-Day Emetogenic Chemotherapy Regimens (page 583).

<sup>i</sup>Monitor for dystonic reactions; use diphenhydramine 25-50 mg PO or IV either every 4 or 6 h for dystonic reactions.

<sup>j</sup>See Principles of Managing Breakthrough Emesis (page 584).

<sup>k</sup>See blackbox warning/label indication regarding type II diabetes, hyperglycemia, and death in elderly dementia patients.

## Antiemesis Version 3:2009

RESPONSE TO BREAKTHROUGH  
ANTIEMETIC TREATMENT

SUBSEQUENT CYCLES

Nausea and emesis controlled → Continue breakthrough medications, on a schedule, not prn

Nausea and/or emesis uncontrolled → Consider changing antiemetic therapy to higher-level primary treatment

See Principles of Emesis Control (page 574)

## EMETOGENIC POTENTIAL OF ANTINEOPLASTIC AGENTS

LEVEL	AGENT
High emetic risk (> 90% frequency of emesis) <sup>1</sup>	<ul style="list-style-type: none"> <li>• AC combination defined as either doxorubicin or epirubicin with cyclophosphamide</li> <li>• Altretamine</li> <li>• Carmustine &gt; 250 mg/m<sup>2</sup></li> <li>• Cisplatin ≥ 50 mg/m<sup>2</sup></li> <li>• Cyclophosphamide &gt; 1500 mg/m<sup>2</sup></li> <li>• Dacarbazine</li> <li>• Mechlorethamine</li> <li>• Procarbazine (oral)</li> <li>• Streptozocin</li> </ul>
Moderate emetic risk (30%-90% frequency of emesis) <sup>1</sup>	<ul style="list-style-type: none"> <li>• Aldesleukin &gt; 12-15 million units/m<sup>2</sup></li> <li>• Amifostine &gt; 300 mg/m<sup>2</sup></li> <li>• Arsenic trioxide</li> <li>• Azacitidine</li> <li>• Bendamustine</li> <li>• Busulfan &gt; 4 mg/d</li> <li>• Carboplatin</li> <li>• Carmustine ≤ 250 mg/m<sup>2</sup></li> <li>• Cisplatin &lt; 50 mg/m<sup>2</sup></li> <li>• Cyclophosphamide ≤ 1500 mg/m<sup>2</sup></li> <li>• Cyclophosphamide (oral)</li> <li>• Cytarabine &gt; 1 g/m<sup>2</sup></li> <li>• Dactinomycin</li> <li>• Daunorubicin</li> <li>• Doxorubicin</li> <li>• Epirubicin</li> <li>• Etoposide (oral)</li> <li>• Idarubicin</li> <li>• Ifosfamide</li> <li>• Imatinib (oral)<sup>m</sup></li> <li>• Irinotecan</li> <li>• Lomustine</li> <li>• Melphalan &gt; 50 mg/m<sup>2</sup></li> <li>• Methotrexate 250 to &gt; 1000 mg/m<sup>2</sup></li> <li>• Oxaliplatin &gt; 75 mg/m<sup>2</sup></li> <li>• Temozolomide (oral)</li> <li>• Vinorelbine (oral)</li> </ul>
Low emetic risk (10%-30% frequency of emesis) <sup>1</sup>	<ul style="list-style-type: none"> <li>• Amifostine ≤ 300 mg</li> <li>• Bexarotene</li> <li>• Capecitabine</li> <li>• Cytarabine (low dose) 100-200 mg/m<sup>2</sup></li> <li>• Docetaxel</li> <li>• Doxorubicin (liposomal)</li> <li>• Etoposide</li> <li>• Fludarabine (oral)</li> <li>• 5-Fluorouracil</li> <li>• Gemcitabine</li> <li>• Ixabepilone</li> <li>• Methotrexate &gt; 50 mg/m<sup>2</sup> &lt; 250 mg/m<sup>2</sup></li> <li>• Mitomycin</li> <li>• Mitoxantrone</li> <li>• Nilotinib</li> <li>• Paclitaxel</li> <li>• Paclitaxel-albumin</li> <li>• Pemetrexed</li> <li>• Topotecan</li> <li>• Vorinostat</li> </ul>
Minimal emetic risk (< 10% frequency of emesis) <sup>1</sup>	<ul style="list-style-type: none"> <li>• Alemtuzumab</li> <li>• Alpha Interferon</li> <li>• Asparaginase</li> <li>• Bevacizumab</li> <li>• Bleomycin</li> <li>• Bortezomib</li> <li>• Busulfan</li> <li>• Cetuximab</li> <li>• Chlorambucil (oral)</li> <li>• Cladribine (2-chlorodeoxyadenosine)</li> <li>• Decitabine</li> <li>• Denileukin diftitox</li> <li>• Desatinib</li> <li>• Dexrazoxane</li> <li>• Erlotinib</li> <li>• Fludarabine</li> <li>• Gefitinib</li> <li>• Gemtuzumab ozogamicin</li> <li>• Hydroxyurea (oral)</li> <li>• Lapatinib</li> <li>• Lenalidomide</li> <li>• Melphalan (oral low-dose)</li> <li>• Methotrexate ≤ 50 mg/m<sup>2</sup></li> <li>• Nelarabine</li> <li>• Panitumumab</li> <li>• Pentostatin</li> <li>• Rituximab</li> <li>• Sorafenib</li> <li>• Sunitinib</li> <li>• Temsirolimus</li> <li>• Thalidomide</li> <li>• Thioguanine (oral)</li> <li>• Trastuzumab</li> <li>• Valrubicin</li> <li>• Vinblastine</li> <li>• Vincristine</li> <li>• Vinorelbine</li> </ul>

Adapted with permission from Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Onc 1997;15:103-109, and Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 2005;13:80-84.

<sup>1</sup>Proportion of patients who experience emesis in the absence of effective antiemetic prophylaxis

<sup>m</sup>Daily use of antiemetics is not recommended based on clinical experience.

Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise noted.

Antiemesis Version 3:2009

EMETOGENIC POTENTIAL	TYPE OF RADIATION THERAPY	EMESIS PREVENTION	BREAKTHROUGH TREATMENT
Radiation-induced nausea/vomiting	RT - upper abdomen	<ul style="list-style-type: none"> <li>• Start pretreatment for each day of RT treatment:</li> <li>• Ondansetron 8 mg PO bid-tid or Granisetron 2 mg PO daily</li> <li>• ± Dexamethasone 2 mg PO tid</li> </ul>	See Breakthrough Treatment (pages 578 and 579)
	Total body irradiation	<ul style="list-style-type: none"> <li>• Start pretreatment for each day of RT treatment:</li> <li>• Ondansetron 8 mg PO bid-tid or Granisetron 2 mg PO daily, or 3 mg IV daily (category 2B)</li> <li>• ± Dexamethasone 2 mg PO tid</li> </ul>	
	Chemotherapy and RT	See emesis prevention for chemotherapy-induced nausea/vomiting (High [page 575], Moderate [page 576], and Low [page 577])	
	RT - other sites	None	Ondansetron, 8 mg PO bid-tid

See Principles of Emesis Control (page 574)

## ANTICIPATORY EMESIS PREVENTION/TREATMENT

Anticipatory nausea/vomiting



## Prevention:

- Use optimal antiemetic therapy during every cycle of treatment

## Behavioral therapy:

- Relaxation/systematic desensitization
- Hypnosis/guided imagery
- Music therapy

Accupuncture/accupressure

Alprazolam 0.5-2 mg PO tid on the night before treatment

Lorazepam 0.5-2 mg PO on night before and morning of treatment

See Principles of Emesis Control (page 574)

## Antiemesis Version 3:2009

### PRINCIPLES OF MANAGING MULTI-DAY EMETOGENIC CHEMOTHERAPY REGIMENS

- Patients undergoing multi-day chemotherapy are at risk for both acute and delayed nausea and emesis based on the emetogenic potential of the individual chemotherapy agents and their sequence. Therefore, recommending a specific antiemetic regimen for each day is difficult, especially because acute and delayed emesis may overlap after the initial day of chemotherapy until the last day of chemotherapy. The period of risk for delayed emesis after conclusion of chemotherapy administration also depends on the specific regimen and the emetogenic potential of the last chemotherapy agent administered in the regimen.
- Examples illustrating the above include BEP (bleomycin 30 units IV weekly, etoposide 100 mg/m<sup>2</sup> IV days 1-5, and cisplatin 20 mg/m<sup>2</sup> IV days 1-5) versus ASHAP (doxorubicin 25 mg/m<sup>2</sup> IV day 1, methylprednisolone 500 mg/day IV days 1-5, cisplatin 25 mg/m<sup>2</sup> IV continuous infusion days 1-4 followed by cytarabine 2000 mg/m<sup>2</sup> on day 5). BEP is moderately emetogenic, with risk for emesis on days 1-8, whereas ASHAP is moderately emetogenic on days 1-4 but becomes highly emetogenic on day 5 because of the administration of high-dose cytarabine. Risk for acute and delayed emesis for ASHAP may last up to 10 days.

Accordingly, the panel recommends the following as general principles (category 2B):

- A 5-HT<sub>3</sub> receptor antagonist should be administered before each day's first dose of moderately or highly emetogenic chemotherapy.
- Dexamethasone should be administered once daily either orally or intravenously for every day of moderately or highly emetogenic chemotherapy and for 2-3 days after chemotherapy for regimens that are likely to cause significant delayed emesis. Dexamethasone should not be added when the chemotherapy regimen already includes a corticosteroid (as in ASHAP illustrated above).
- Intravenous palonosetron may be used before the start of a 3-day chemotherapy regimen instead of multiple daily doses of oral or intravenous 5-HT<sub>3</sub> receptor antagonists. Repeat dosing of palonosetron, 0.25 mg IV, is likely to be safe, based on the dose-ranging phase II trial in which up to 30 times the FDA-approved dose (90 mcg/kg) was administered, and the 3 phase III trials that evaluated palonosetron, 0.75 mg, as a single fixed dose. Compared with the approved dose of palonosetron, 0.25 mg, these higher doses were not associated with significantly different grades or durations of adverse events. In terms of efficacy, need for repeat dosing with palonosetron, either daily or less frequently, in the setting of multiday chemotherapy is not yet known.
- Aprepitant may be used for multi-day chemotherapy regimens likely to be highly emetogenic and associated with significant risk for delayed nausea and emesis. As per the labeled indication, aprepitant should be administered as 125 mg orally 1 hour before chemotherapy on day 1, along with a 5-HT<sub>3</sub> receptor antagonist and dexamethasone. Aprepitant, 80 mg, should be administered daily on days 2 and 3 after the start of chemotherapy along with dexamethasone. Based on phase II data, aprepitant, 80 mg, may be safely administered on days 4 and 5 after chemotherapy. It is not yet known if dosing aprepitant after day 3 improves control of nausea or emesis in this clinical setting.

## PRINCIPLES FOR MANAGING BREAKTHROUGH EMESIS

- Breakthrough emesis presents a difficult situation as correction of refractory ongoing nausea and vomiting is often challenging to reverse. Generally, nausea and vomiting are far easier to prevent than to treat.
- The general principle of breakthrough treatment is to give an additional agent from a different drug class. No one treatment is better than another for managing breakthrough emesis.
- Clinicians should strongly consider routine around-the-clock, administration rather than PRN dosing.
- The oral route is not likely to be feasible because of ongoing vomiting; therefore, rectal or IV therapy is often required.
- Multiple concurrent agents, perhaps in alternating schedules or by alternating routes, may be necessary. Dopamine antagonists (e.g., metoclopramide), haloperidol, corticosteroids, and agents such as lorazepam may be required.
- Adequate hydration or fluid repletion should be ensured, with simultaneous checking and correcting of any possible electrolyte abnormalities.
- Before the next cycle of chemotherapy is administered, patients should be reassessed, with attention to various possible nonchemotherapy-related reasons for breakthrough emesis with the current cycle, such as:
  - ▶ Brain metastases
  - ▶ Electrolyte abnormalities
  - ▶ Tumor infiltration of the bowel or other gastrointestinal abnormality
  - ▶ Other comorbidities
- Before the next cycle of chemotherapy, clinicians should reassess both the day 1 and postchemotherapy antiemetic regimen that did not protect the patient during the present cycle, and consider alternatives, such as (suggestions are not in order of preference):
  - ▶ Addition of aprepitant
  - ▶ Addition of other concomitant antiemetics (e.g., dopamine antagonists [metoclopramide], haloperidol)
  - ▶ Possibly adjusting dose(s), either intensity or frequency, of the 5-HT<sub>3</sub> antagonist. Based on the patient's experiences, the chemotherapy regimen in question may actually be more emetogenic than generally classified (e.g., Hesketh method)
  - ▶ Possibly switching to a different 5-HT<sub>3</sub>; although not necessarily likely to be effective, anecdotal and limited investigational trial data suggest this may sometimes be efficacious
  - ▶ If the goal of chemotherapy is palliative or adjuvant, consider other appropriate regimens, if any, that might be less emetogenic
  - ▶ Adding an anxiolytic agent in combination with the antiemetic agents
- If patient has dyspepsia, antacid therapy (H<sub>2</sub> blocker or proton pump inhibitor) should be considered.

Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise noted.

Text continued from p. 573

ing the course of emesis, or behave synergistically with other antiemetic agents to potentiate an antiemetic effect. When used at a certain concentration, each antiemetic agent predominantly blocks one receptor type. A final common pathway for emesis has not been identified. Therefore, no single agent can be expected to provide complete protection from the various emetic phases of chemotherapy.

## Types of Nausea and/or Vomiting

### Chemotherapy-Induced Nausea and/or Vomiting

Nausea and/or vomiting induced by chemotherapy is commonly classified as acute, delayed, anticipatory, breakthrough, or refractory. *Acute-onset* nausea and/or vomiting usually occurs within a few minutes to several hours after drug administration and commonly resolves within the first 24 hours. The intensity of acute emesis generally peaks after 5 to 6 hours, and its occurrence is influenced by patient age and gender (women and patients < 50 years are more prone), environment in which chemotherapy is administered, whether the patient has a history of chronic alcoholism (decreases the incidence of emesis) or motion sickness, previous episodes of nausea and vomiting, dosage of the emetogenic agent, and efficacy of the antiemetic regimen.<sup>16,17</sup>

*Delayed-onset* nausea and/or vomiting develops in patients more than 24 hours after chemotherapy is administered<sup>16,17</sup> and commonly occurs when cisplatin, carboplatin, cyclophosphamide, and/or doxorubicin are used. For cisplatin, emesis reaches its maximal intensity 48 to 72 hours after chemotherapy and can last 6 to 7 days.

*Anticipatory nausea* and/or vomiting occurs before patients undergo their next chemotherapy treatment. Because it is a conditioned response, anticipatory emesis can occur only after a negative past experience with chemotherapy. The incidence of anticipatory nausea and/or vomiting ranges from 18% to 57%, with nausea being more common than vomiting.<sup>18,19</sup> Younger patients may be more susceptible, because they are generally treated with more aggressive chemotherapy and, overall, have poorer emesis control than older patients.<sup>20</sup> *Breakthrough* emesis refers to vomiting that occurs despite prophylactic treatment and/or requires rescue with antiemetic agents. *Refractory* emesis refers to emesis that occurs during subsequent treatment cycles when antiemetic prophylaxis and/or rescue have failed in earlier cycles.

### Radiation-Induced Nausea and/or Vomiting

Patients undergoing whole body or upper abdominal radiation therapy have the greatest likelihood of developing nausea and/or vomiting.<sup>21,22</sup> The gastrointestinal tract (specifically the small intestine) contains rapidly dividing cells that are particularly sensitive to radiation. In addition, the potential for nausea and vomiting increases with larger daily fractional doses of radiotherapy, larger total doses, and larger amounts of irradiated tissue. Total body irradiation, when given before bone marrow transplantation, also commonly induces nausea and/or vomiting.<sup>22,23</sup>

### Emetogenicity of Chemotherapy

The frequency of chemotherapy-induced emesis depends primarily on the emetogenic potential of the specific chemotherapeutic agents used. Several classifications have been developed to define the emetogenicity of chemotherapy; however, none have been universally accepted.<sup>12,24–27</sup>

Hesketh et al.<sup>28</sup> developed a classification of acute emetogenicity for anticancer chemotherapeutic agents and an algorithm to define the emetogenicity of combination chemotherapeutic regimens. The classification, which was updated by Grunberg et al.,<sup>29</sup> divides chemotherapeutic agents into 4 levels according to the percentage of patients not receiving antiemetic prophylaxis who experience acute emesis. This classification, which was updated with recently introduced drugs, is used in these guidelines. Panel members from all of the published antiemetic treatment guidelines met to prepare a single consensus document. Although this process is ongoing, the consensus guidelines have been published.<sup>30</sup> These guidelines currently outline treatment using 4 categories of emetogenic potential (see page 580), which correspond to the Grunberg classification as follows:

- High emetic risk: 90% or more of patients experience acute emesis
- Moderate emetic risk: 30% to 90% of patients experience acute emesis
- Low emetic risk: 10% to 30% of patients experience acute emesis
- Minimal emetic risk: fewer than 10% of patients experience acute emesis

These guidelines also attempt to define antiemetic regimens for particular chemotherapy drugs that cover the entire period a patient is at risk for

## Antiemesis

nausea and vomiting. Panel members were concerned that some patients may not receive adequate prophylaxis for delayed emesis, and therefore the algorithms were revised for high and moderate emetogenic potential agents to incorporate a dosing schedule that covers both acute and delayed emesis into a single algorithm.

### Types of Antiemetic Therapies

In general, to provide maximal protection against chemotherapy-induced emesis, antiemetic therapy should be initiated before chemotherapy and continued for the duration of the emetic activity according to the chemotherapeutic agent being used. However, daily use of antiemetics is not recommended for some therapeutic agents that are taken long-term (i.e., imatinib; see page 580). Antiemetic agents can be administered orally, rectally, intravenously, intramuscularly, or transdermally. Compared with other routes of administration, oral formulations of antiemetic agents are equally effective and safe, while being more convenient and less costly. For patients unable to swallow or digest tablets because of emesis, intravenous antiemetics are required. In selected patients unable to swallow, transdermal antiemetics may be of value. Although studies may show drugs to be equally effective on a population basis, individual patients may respond differently. Therefore, some drug options may be based on a patient's individual experience.

#### Serotonin (5-HT<sub>3</sub>) Receptor Antagonists

The development of the 5-HT<sub>3</sub>-receptor antagonists (i.e., ondansetron, granisetron, dolasetron mesylate, palonosetron) represent a significant advance in antiemetic therapy.<sup>31-33</sup> All agents have been shown to be effective in controlling acute chemotherapy-induced nausea and/or vomiting.<sup>33-47</sup>

Palonosetron is a 5-HT<sub>3</sub> antagonist with approximately a 100-fold higher binding affinity for the 5-HT<sub>3</sub> receptor compared with other serotonin antagonists (e.g., ondansetron, granisetron, dolasetron). It has a half-life of approximately 40 hours, which is significantly longer than other commercially available 5-HT<sub>3</sub> antagonists.<sup>33</sup> Initial studies in patients undergoing moderately emetogenic chemotherapy showed that a single intravenous dose of palonosetron was comparable to the same dose of dolasetron for preventing acute chemotherapy-induced nausea and emesis. However, intravenous

palonosetron was superior in preventing delayed emesis.<sup>48</sup> The safety and side-effect profiles of palonosetron were indistinguishable from the control 5-HT<sub>3</sub> antagonists (ondansetron and dolasetron) according to data submitted to the FDA.

Intravenous palonosetron is FDA-approved as a single dose on day 1. It is recommended (category 1) for preventing acute and delayed emesis associated with moderately emetogenic chemotherapy<sup>48</sup> and is superior to other 5-HT<sub>3</sub> antagonists in preventing delayed nausea.<sup>49</sup> However, repeat dosing of palonosetron in the days after chemotherapy (days 2 or 3) is not supported by scientific literature. Repeat dosing of palonosetron in the setting of multi-day chemotherapy regimens has not been studied.

Many 5-HT<sub>3</sub> antagonists can be delivered orally or intravenously. In addition, the FDA recently approved the use of a granisetron transdermal system for chemotherapy-induced nausea and vomiting (<http://www.fda.gov/cder/foi/label/2008/0221981bl.pdf>). The patch, containing 34.3 mg of granisetron, is applied 24 to 48 hours before the first dose of chemotherapy. A phase III randomized study compared the patch with oral granisetron in patients undergoing either highly or moderately emetogenic chemotherapy, and it proved to be noninferior to repeat dosing of the oral antiemetic granisetron over 3 to 5 days.<sup>50</sup>

Many clinical trials directly comparing ondansetron, granisetron, dolasetron mesylate, and palonosetron have been conducted. These trials have used various doses, routes, and schedules of administration,<sup>48,51-70</sup> and have shown that 5-HT<sub>3</sub> antagonists are equally effective and have mild infrequent side effects. A recent meta-analysis found no difference in efficacy.<sup>71</sup> Adding dexamethasone improves the efficacy of antiemetic regimens containing 5-HT<sub>3</sub> antagonists.

Ondansetron, granisetron, and dolasetron are effective in preventing acute emesis, but seem to be less effective in preventing delayed emesis. However, intravenous palonosetron is effective for preventing both delayed and acute emesis. A meta-analysis of randomized controlled trials found that adding a 5-HT<sub>3</sub> antagonist to dexamethasone did not improve its ability to prevent delayed emesis.<sup>72</sup> Another study found that 5-HT<sub>3</sub> antagonists (except palonosetron, which was not studied) were not more effective than prochlorperazine in preventing delayed emesis.<sup>11</sup>

### NK-1–Receptor Antagonist

Aprepitant selectively blocks the binding of substance P at the NK-1 receptor in the central nervous system, providing a different and complementary mechanism of action to all other commercially available antiemetics. Aprepitant has been shown to augment the antiemetic activity of 5-HT<sub>3</sub>–receptor antagonists and corticosteroid dexamethasone, inhibiting both acute and delayed cisplatin-induced emesis. The FDA has approved the use of aprepitant for preventing emesis in patients undergoing moderately emetogenic chemotherapy. An intravenous version of aprepitant (fosaprepitant dimeglumine), which can be given on day 1 only, was recently approved by the FDA (<http://www.fda.gov/cder/foi/label/2008/0220231bl.pdf>).

When combined with 5-HT<sub>3</sub> antagonists and dexamethasone on day 1 (125 mg)<sup>73</sup> before cisplatin-based highly emetogenic chemotherapy, and continued orally with dexamethasone on days 2 and 3 (80 mg)<sup>73</sup> after chemotherapy, aprepitant significantly improved control of acute and delayed chemotherapy-induced nausea and emesis.<sup>74,75</sup> No studies show efficacy or safety of chronic dosing with aprepitant; the drug–drug interaction profile may change with chronic dosing.

A randomized phase III study (866 patients) showed that an aprepitant regimen (aprepitant, ondansetron, and dexamethasone) is better than a standard regimen (ondansetron and dexamethasone) for preventing vomiting in patients undergoing moderately emetogenic chemotherapy (non–cisplatin-based) within 120 hours after initiation of chemotherapy (complete response, 50.8% vs. 42.5%;  $P = .015$ ); however, 40% of patients (undergoing either regimen) still experienced significant nausea.<sup>76,77</sup> An analysis of 2 phase III randomized trials found that an aprepitant regimen is useful for treating patients undergoing moderately emetogenic chemotherapy plus high-dose cisplatin.<sup>78</sup>

A meta-analysis of 7 randomized controlled trials of patients undergoing highly emetogenic chemotherapy found that NK-1 receptor antagonists used alone or with standard therapy for acute emesis were not better than the control; however, for delayed emesis, NK-1 receptor antagonists were better than the control.<sup>79</sup> A phase II study of 58 patients found that combining palonosetron, aprepitant, and dexamethasone was useful for various chemotherapeutic

regimens (moderate to moderate-to-highly emetogenic); 78% experienced a complete response (no emetic episodes or rescue medication).<sup>80</sup>

**Drug Interactions:** Aprepitant is simultaneously a substrate, moderate inducer, and moderate inhibitor of cytochrome P450 enzyme 3A4 (CYP3A4); aprepitant also induces CYP2C9.<sup>81</sup> Therefore, aprepitant can alter the metabolism of certain drugs and change their plasma concentrations (area under the curve [AUC]). These interactions are more significant with orally administered forms than with intravenous forms because of first-pass metabolism. Patients should not take aprepitant with pimozide, terfenadine, astemizole, or cisapride; these combinations are contraindicated because they may cause “serious or life-threatening reactions.”<sup>82</sup>

Chemotherapeutic agents known to be metabolized by CYP3A4 include docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine, and vincristine. In clinical trials, aprepitant was used concurrently with etoposide, vinorelbine, or paclitaxel; although chemotherapy doses were not adjusted for potential drug interactions in phase III trials, caution is urged when using any chemotherapeutic agent metabolized by CYP3A4.

Aprepitant has been shown to interact with several non-chemotherapeutic drugs (including warfarin, dexamethasone, methylprednisolone, oral contraceptives). Again, these interactions are more significant with orally administered forms of these drugs than with intravenous forms because of first-pass metabolism.

Induction of warfarin metabolism by aprepitant may lead to clinically significant reductions in international normalized ratio values, particularly for patients on therapeutic (vs. prophylactic) warfarin regimens. These changes, although brief in duration, may require increased patient monitoring (<http://www.fda.gov/cder/foi/label/2008/021549s0151bl.pdf>).

Aprepitant decreases the AUC for patients taking oral contraceptives; the package insert should be consulted in this setting. Certain drugs can affect the AUCs of aprepitant. Concomitant administration with CYP3A4 inhibitors (i.e., ketoconazole, itraconazole, erythromycin) may lead to increased aprepitant AUCs, whereas concomitant administration with CYP3A4 inducers (i.e., carbamazepine, rifampin, phenytoin) may lead to decreased levels of aprepitant.

## Antiemesis

**Other Non-5-HT<sub>3</sub>-Receptor Antagonist Antiemetics**

Before the advent of the 5-HT<sub>3</sub>-receptor antagonists, available antiemetic agents included phenothiazines,<sup>83</sup> substituted benzamides,<sup>84,85</sup> antihistamines,<sup>86</sup> butyrophenones,<sup>87</sup> corticosteroids,<sup>88-90</sup> benzodiazepines,<sup>91,92</sup> and cannabinoids.<sup>93,94</sup> Most drugs used to prevent chemotherapy-induced emesis are classified as dopamine antagonists, serotonin antagonists, and other antagonists. Combination antiemetic therapy is more effective than single-agent therapy. Olanzapine (thiobenzodiazepine) was found to be effective for acute and delayed emesis in a phase II trial in patients (n = 30) treated with cyclophosphamide, doxorubicin, and/or cisplatin;<sup>95,96</sup> other studies have also shown the value of olanzapine for delayed and refractory emesis and nausea.<sup>97-100</sup> However, olanzapine should be used with caution in elderly patients (see boxed warning/label indication regarding death, type II diabetes, and hyperglycemia [<http://www.fda.gov/cder/foi/label/2007/020592s042s043,021086s022s023,021253s026lbl.pdf>]).<sup>101</sup>

**Treatment Issues**

Selected issues that arose in the panel deliberations are discussed in the following sections. When caring for patients undergoing chemotherapy, clinicians should consider new data that may become available on the use of antiemetics, even if the information was not included in the guidelines. In contrast to other NCCN guidelines in which most of the recommendations are category 2A, many recommendations for antiemetic management are classified as category 1, reflecting the large number of randomized controlled trials that have focused on antiemetic management.

**Principles of Emesis Control**

These principles are discussed in the algorithm (see page 574).

- The goal is to prevent nausea and/or vomiting.
- The risk for emesis and nausea for persons undergoing chemotherapy of high and moderate emetogenic potential lasts at least 4 days for high and 3 days for moderate. Patients must be protected throughout the full period of risk.
- Oral and intravenous antiemetic formulations have equivalent efficacy.
- The toxicity of the specific antiemetic(s) should be considered.

- Antiemetic regimens should be chosen based on the drug with the highest emetic risk in the chemotherapy regimen, previous experience with antiemetics, and patient-specific risk factors.

In addition to emesis induced by chemotherapy, emesis in patients with cancer can also potentially be caused by:

- Partial or complete bowel obstruction
- Vestibular dysfunction
- Brain metastases
- Electrolyte imbalance: hypercalcemia, hyperglycemia, hyponatremia
- Uremia
- Concomitant drug treatments, including opiates
- Gastroparesis induced by a tumor or chemotherapy (e.g., vincristine)
- Psychophysiologic factors, including anxiety, anticipatory nausea, and vomiting
- For the use of antiemetics for nausea and vomiting that is not related to radiation and/or chemotherapy, see the NCCN Clinical Practice Guidelines in Oncology: Palliative Care (to view the most recent version of these guidelines, visit the NCCN Web site at [www.nccn.org](http://www.nccn.org))
- For multidrug regimens, select antiemetic therapy based on drug with the highest emetic risk (see page 580).<sup>28,29</sup>

**Prevention of Acute Emesis**

To prevent acute emesis, antiemetic therapy should start before the administration of chemotherapy and cover the first 24 hours. For highly emetogenic drugs, the regimens are described on page 575. For moderately emetogenic drugs, the regimens are described on page 576. For low and minimally emetogenic drugs, the regimens are described on page 577. This section discusses prechemotherapy and postchemotherapy emesis prevention rather than primary treatment.

**Prechemotherapy Emesis Prevention:** The guidelines specify different prophylactic antiemetic regimens for patients with cancer undergoing chemotherapy of different emetogenic potential (e.g., high, moderate, low, minimal). Prophylactic antiemetics should be administered before chemotherapy, and recommendations for treatment include drug dosages. The guidelines reflect accumulating experience with 5HT<sub>3</sub>-serotonin antagonists, showing their effectiveness in a range of doses. Unless indicated, the order of listed antiemetics in the algorithm does not reflect preference.

## Antiemesis

Highly emetogenic drugs include altretamine, carmustine ( $> 250 \text{ mg/m}^2$ ), cisplatin ( $\geq 50 \text{ mg/m}^2$ ), cyclophosphamide ( $> 1500 \text{ mg/m}^2$ ), dacarbazine, mechlorethamine, procarbazine (oral), streptozocin, or anthracycline and cyclophosphamide (AC) combinations (doxorubicin or epirubicin with cyclophosphamide). The antiemetic regimen for these highly emetogenic drugs on day 1 includes aprepitant (or fosaprepitant), dexamethasone, and a 5-HT<sub>3</sub> antagonist with or without lorazepam and with or without either an H<sub>2</sub> blocker or proton pump inhibitor (category 1 for combined regimen [see page 575]);<sup>22,23,74</sup> note that the regimen and doses are often modified on days 2 to 4 after chemotherapy. Although any 5-HT<sub>3</sub> antagonist can be used, palonosetron is preferred (category 2B) in combination with dexamethasone and aprepitant for patients undergoing chemotherapy of high emetic risk based on results from a recent randomized study.<sup>102</sup> However, this study used a larger dose of palonosetron and did not use aprepitant.

A Canadian meta-analysis suggests that using 5-HT<sub>3</sub> antagonists (e.g., ondansetron) on days 2 to 4 to prevent delayed emesis is not cost-effective; however, ondansetron (when used alone) protected against delayed emesis.<sup>103</sup> Palonosetron was not assessed in these studies. The NCCN Antiemesis Panel recommends using 5-HT<sub>3</sub> antagonists as one of several options to prevent delayed emesis associated with moderately emetogenic agents (see page 576).

The antiemetic regimen for moderately emetogenic drugs (see page 580) on day 1 includes dexamethasone and a 5-HT<sub>3</sub> antagonist with or without lorazepam and/or either an H<sub>2</sub> blocker or proton pump inhibitor (see page 576).<sup>77</sup> Aprepitant should be added (to dexamethasone and a 5-HT<sub>3</sub> antagonist) for select patients undergoing other chemotherapies of moderate emetic risk (i.e., carboplatin, cisplatin, doxorubicin, epirubicin, ifosfamide, irinotecan, or methotrexate; see page 576), because these agents are more emetogenic than the other moderately emetogenic agents.<sup>23,28</sup> Any of the 5HT<sub>3</sub> antagonists can be used because they are all category 1. Note that the regimens differ on days 2 to 3 because 3 possible regimens are available (lorazepam and/or either an H<sub>2</sub> blocker or a proton pump inhibitor may be added to each of these regimens), including 1) aprepitant with or without dexamethasone, 2) dexamethasone, or 3) 5HT<sub>3</sub> antagonist, such as ondansetron, granisetron, or dolasetron. Note that palonosetron is not given on days 2 to 3.

The antiemetic regimen for low emetogenic drugs (see page 580) includes non-5-HT<sub>3</sub> antagonists, such as dexamethasone, prochlorperazine, or metoclopramide, with or without lorazepam and/or either an H<sub>2</sub> blocker or proton pump inhibitor (see page 577). When using prochlorperazine or metoclopramide, patients should be monitored for dystonic reactions; diphenhydramine (25–50 mg orally or intravenously either every 4 or 6 hours) can be used for dystonic reaction.

For regimens with high emetogenic potential, aprepitant is used at an oral dosage of 125 mg on day 1, and 80 mg on days 2 and 3 (see page 575). When given with aprepitant, dexamethasone is used at an oral or intravenous dosage of 12 mg. All of the 5-HT<sub>3</sub>-receptor antagonists (i.e., ondansetron, granisetron, dolasetron, palonosetron) are considered to have similar effectiveness for controlling acute emesis. If appropriate, lorazepam (0.5–2 mg either every 4 or 6 hours on days 1–4; either oral, intravenous, or sublingual) may be used with each of these regimens (e.g., high, moderate, or low).

**Postchemotherapy/Delayed Emesis Prevention:**

The best management for delayed emesis is prevention. For chemotherapy involving agents with high emetogenic potential, prophylactic treatment is continued through the period when delayed emesis may occur. Using this strategy, prophylaxis continues for 2 to 3 days after completion of a chemotherapy cycle.

For drugs with moderate emetogenic potential, postchemotherapy prevention depends on what antiemetics were used before chemotherapy. For example, palonosetron (category 1) is only administered on day 1 (see page 576).<sup>51</sup> If aprepitant was used on day 1, then it is continued on days 2 and 3 and is given with or without dexamethasone, lorazepam, and/or either an H<sub>2</sub> blocker or proton pump inhibitor. Alternatively, either dexamethasone or a 5-HT<sub>3</sub> antagonist can be used; lorazepam and/or either an H<sub>2</sub> blocker or proton pump inhibitor may be used with either agent.

**Breakthrough Treatment**

Breakthrough emesis presents a difficult situation, because refractory ongoing nausea and/or vomiting is often challenging to reverse (see page 584). Generally, it is much easier to prevent nausea and/or vomiting than to treat it. Thus, routine around-

## Antiemesis

the-clock administration of antiemetics should be strongly considered to prevent emesis, rather than PRN (as required) dosing. The general principle of breakthrough treatment is to give an additional agent as needed from a different drug class. However, no one treatment is better than another for managing this condition.<sup>104</sup> The oral route is not likely to be feasible because of ongoing vomiting; therefore, rectal or intravenous therapy is often required.

Multiple concurrent agents, perhaps in alternating schedules or by alternating routes, may be necessary. Dopamine antagonists (i.e., metoclopramide), haloperidol, corticosteroids, and agents such as lorazepam may be required. Nabilone (cannabinoid) is approved by the FDA for nausea and vomiting in patients who have not responded to conventional antiemetic agents. Adequate hydration or fluid repletion should be ensured and any possible electrolyte abnormalities assessed and corrected. Before the next cycle of chemotherapy is administered, patients should be reassessed with attention to various possible non-chemotherapy-related reasons for breakthrough emesis with the current cycle, such as brain metastases, electrolyte abnormalities, tumor infiltration of the bowel, other gastrointestinal abnormalities, and other comorbidities (see page 584). In addition, before the next cycle of chemotherapy, the antiemetic regimen (both day 1 and postchemotherapeutic) that failed during the present cycle should be assessed and alternatives considered (see page 584). Antacid therapy (i.e., proton pump inhibitors, H<sub>2</sub> blockers) should be considered if patients have dyspepsia, because patients sometimes have difficulty discriminating heartburn from nausea.

**Radiation-Induced Nausea and/or Vomiting**

Prophylaxis for radiation-induced nausea and/or vomiting is based on the site of radiation and whether it is combined with chemotherapy (see page 581). When radiation is combined with chemotherapy, prophylaxis is dictated by the emetogenic potential of the chemotherapy regimen.

Radiation to the upper abdomen may be treated with oral ondansetron (8 mg, 2–3 times daily), with or without oral dexamethasone, based on the results of a randomized study comparing oral ondansetron with placebo in patients undergoing daily fractionated radiotherapy that included the abdomen. In this study, 67% of patients given ondansetron experienced complete control of emesis compared with

45% of patients who received placebo.<sup>105</sup> A study showed that the addition of oral dexamethasone (4 mg daily) to the ondansetron regimen decreases emesis and nausea, although the effect is modest.<sup>106</sup> Another option is oral granisetron (2 mg daily) with or without oral dexamethasone.

Total body irradiation may be treated with either ondansetron (8 mg, 2–3 times daily) or granisetron; either agent can be given with or without oral dexamethasone (2 mg, 3 times daily).<sup>106</sup> The dose of granisetron is either 2 mg orally every day or 3 mg intravenously every day<sup>107,108</sup> (category 2B, because this dose of granisetron is higher than the dose typically used). No prophylaxis is recommended for patients undergoing irradiation to other sites.

Treatment of breakthrough radiation-induced emesis is similar to chemotherapy-induced emesis. Patients who do not receive primary prophylaxis and experience breakthrough nausea and/or vomiting may be treated with ondansetron, similar to primary prophylaxis.

**Anticipatory Nausea and/or Vomiting**

The most effective way to treat anticipatory nausea and/or vomiting is to prevent it by using optimal antiemetic therapy during every cycle of treatment (see page 582). Behavioral therapy has been used in patients with anticipatory nausea and/or vomiting.<sup>109–111</sup> Systematic desensitization may also be helpful.<sup>110</sup> Hypnosis with guided imagery is another behavioral technique that has shown some success in treating this condition.<sup>111</sup> The anti-anxiety agents lorazepam and alprazolam have been combined with antiemetics for anticipatory nausea and/or vomiting with mixed results.<sup>112</sup> The usual starting dose of alprazolam is 0.25 to 0.5 mg orally 3 times daily, beginning the night before treatment. In elderly patients or those with debilitating or advanced liver disease, the usual starting dose of alprazolam is 0.25 mg orally 2 or 3 times daily for treatment of anxiety.<sup>113</sup> This dose may be gradually increased if needed. Elderly are especially sensitive to the effects of benzodiazepines. The dose should be gradually reduced when decreasing or discontinuing alprazolam therapy.

**Managing Multiday Emetogenic Chemotherapy Regimens**

Patients undergoing multiday chemotherapy are at risk for both acute and delayed nausea and vomiting

## Antiemesis

based on the emetogenic potential of the individual chemotherapy agents and their sequence.<sup>75,114–117</sup> A specific antiemetic regimen for each day is difficult to recommend, especially because acute and delayed emesis may overlap after the initial day of chemotherapy until the last day of chemotherapy. The period of risk for delayed emesis after the conclusion of chemotherapy also depends on the specific regimen and emetogenic potential of the last chemotherapy agent administered in the regimen. The algorithm describes general principles recommended by the panel for managing multiday emetogenic chemotherapy regimens (category 2B; see page 583).

## References

- Laszlo J. Emesis as limiting toxicity in cancer chemotherapy. In: Laszlo J, ed. *Antiemetics and Cancer Chemotherapy*. Baltimore: Williams & Wilkins; 1983:1–5.
- Ingle RJ, Burish TG, Wallston KA. Conditionability of cancer chemotherapy patients. *Oncol Nurs Forum* 1984;11:97–102.
- Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. *Semin Oncol* 1992;19:566–579.
- Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. *J Clin Oncol* 1988;5:1746–1752.
- Morran C, Smith DC, Anderson DA, et al. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. *Br Med J* 1979;1:1323–1324.
- Jenks K. Importance of nausea. *Cancer Nurs* 1994;17:488–493.
- Nesse RM, Carli T, Curtis GC, et al. Pretreatment nausea in cancer chemotherapy: a conditioned response? *Psychosom Med* 1980;42:33–36.
- Wilcox PM, Fetting JH, Nettesheim KM, et al. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. *Cancer Treat Rep* 1982;66:1601–1604.
- Carey MP, Burish TG. Anxiety as a predictor of behavioral therapy outcome for cancer chemotherapy patients. *J Consult Clin Psychol* 1985;53:860–865.
- Morrow GR, Lindke J, Black PM. Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. *J Pain Symptom Manag* 1991;6:215–223.
- Hickok JT, Roscoe JA, Morrow GR, et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. *Lancet Oncol* 2005;6:765–772.
- Craig JB, Powell BL. The management of nausea and vomiting in clinical oncology. *Am J Med Sci* 1987;293:34–44.
- Borison HL, Wang S. Physiology and pharmacology of vomiting. *Pharmacol Rev* 1953;5:193–230.
- Siegel LJ, Longo DL. The control of chemotherapy-induced emesis. *Ann Intern Med* 1981;95:352–359.
- Dodds LJ. The control of cancer chemotherapy-induced nausea and vomiting. *J Clin Hosp Pharm* 1985;10:143–166.
- Kris MG, Gralla RJ, Clark RA, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. *J Clin Oncol* 1985;3:1379–1384.
- Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin patients and anti-emetic activity and tolerability of metoclopramide or dexamethasone. *Am J Clin Oncol* 1991;14:238–242.
- Moher D, Arthur AZ, Peter JL. Anticipatory nausea and/or vomiting in chemotherapy patients. *Cancer Treat Rev* 1984;11:257–264.
- Jacobsen PB, Redd WH. The development and management of chemotherapy-related anticipatory nausea and vomiting. *Cancer Invest* 1988;6:329–336.
- Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. *J Clin Oncol* 1984;2:1170–1176.
- Harding RK, Young RW, Anno GH. Radiotherapy-induced emesis. In: Andrews PLR, Sanger GJ, eds. *Emesis in Anti-Cancer Therapy*. London: Chapman & Hall Medical; 1993:163–178.
- Roila F, Hesketh PJ, Herrstedt J, et al. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. *Ann Oncol* 2006;17:20–28.
- Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. *J Clin Oncol* 2006;24:2932–2947.
- Laszlo J. Treatment of nausea and vomiting caused by cancer chemotherapy. *Cancer Treat Rev* 1982;9:3–9.
- Strum SB, McDermed JE, Pileggi J, et al. Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. *Cancer* 1984;53:1432–1439.
- Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. *J Clin Oncol* 1989;7:1142–1149.
- Aapro MS. Methodological issues in anti-emetic studies. *Invest New Drugs* 1993;11:243–253.
- Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. *J Clin Oncol* 1997;15:103–109.
- Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. *Support Care Cancer* 2005;13:80–84.
- Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. *Support Care Cancer* 2002;10:519–522.
- Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. *J Natl Cancer Inst* 1991;83:613–620.
- Andrews PL, Bhandari P, Davey PT, et al. Are all 5-HT<sub>3</sub> receptor antagonists the same? *Eur J Cancer* 1992;28A(Suppl 1):S2–6.
- Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT<sub>3</sub>-receptor antagonist for the prevention of chemotherapy-induced emesis. *Expert Opin Pharmacother* 2003;4:2297–2303.
- Grunberg SM, Stevenson LL, Russell CA, et al. Dose-ranging phase I study of the serotonin antagonist GR 38032F for prevention of cisplatin-induced nausea and vomiting. *J Clin Oncol* 1989;7:1137–1141.
- Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients

## Antiemesis

- receiving high-dose cisplatin in a single-blind study. *Eur J Cancer* 1990;26:S33–36.
36. Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. *Eur J Cancer* 1990;26:S23–27.
  37. DeMulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. *Ann Intern Med* 1990;113:834–840.
  38. Marty M. A comparative study of the use of granisetron, a selective 5-HT<sub>3</sub> antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. *Eur J Cancer* 1990;26(Suppl 1):S28–32.
  39. Marty M, Pouillart P, School S, et al. Comparison of the 5-hydroxytryptamine<sub>3</sub> (serotonin) receptor antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. *N Engl J Med* 1990;322:816–821.
  40. Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. *Eur J Cancer* 1990;26(Suppl 1):S15–19.
  41. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. *J Clin Oncol* 1991;9:675–678.
  42. Frascini G. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy. *Semin Oncol* 1992;19(4 Suppl 10):S41–47.
  43. Kamanabrou D. Intravenous granisetron establishing the optimal dose. *Eur J Cancer* 1992;28A(Suppl 1):S6–11.
  44. Sledge GW Jr, Einhorn L, Nagy C, et al. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. *Cancer* 1992;70:2524–2528.
  45. Chevallier B. The control of acute cisplatin-induced emesis—a comparative study of granisetron and combination regimen of high-dose metoclopramide and dexamethasone. *Br J Cancer* 1993;68:176–180.
  46. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of granisetron, a selective 5-HT antagonist, in the prevention of nausea and vomiting induced by high dose cisplatin. *J Clin Oncol* 1994;12:2204–2210.
  47. Riviere A. Dose-finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. *Br J Cancer* 1994;69:967–971.
  48. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT<sub>3</sub> receptor antagonist: results of a phase III, single-dose trial versus dolasetron. *Cancer* 2003;98:2473–2482.
  49. Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology. *Ther Clin Risk Manag* 2007;3:1009–1020.
  50. Grunberg S, Gabriel N, Clark G. Phase III trial of transdermal granisetron patch (Sancuso) compared to oral granisetron (OG) for chemotherapy-induced nausea and vomiting (CINV) after multi-day moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapy [Abstract]. *MASCC/ISOO 20th Anniversary International Symposium Supportive Care in Cancer*, St. Gallen, Switzerland; June 27–30, 2007:687. Abstract P-18.
  51. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. *Ann Oncol* 2003;14:1570–1577.
  52. Bonnetterre J, Hecquet B. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. A crossover study. *Bull Cancer* 1995;82:1038–1043.
  53. Jantunen IT, Kataja VV, Johansson RT. Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute nausea and vomiting induced by non-cisplatin-containing chemotherapy. *Acta Oncol* 1992;31:573–575.
  54. Jantunen IT, Muhonen TT, Kataja VV, et al. 5-HT<sub>3</sub> receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study. *Eur J Cancer* 1993;29A:1669–1672.
  55. Martoni S, Angelelli B, Guaraldi M, et al. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cisplatin-induced emesis: an open randomized cross-over study. *Am Soc Clin Oncol* 1993;13:431.
  56. Campora LE, Simoni C, Rosso R. [Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast carcinoma]. *Minerva Med* 1994;85:25–31 [in Italian].
  57. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. *Cancer* 1994;74:1945–1952.
  58. Mantovani A, Maccio L, Curreli L, et al. Comparison of the effectiveness of three 5-HT<sub>3</sub> receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer. *Proc Am Soc Clin Oncol* 1994;13:428.
  59. Massidda B, Laconi S, Foddi MR, et al. Prevention of non-cisplatin induced emesis: role of the antagonists of 5-HT receptors. *Ann Oncol* 1994;5:S204.
  60. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. *Eur J Cancer* 1994;30:1083–1088.
  61. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. *Oncology* 1994;51:113–118.
  62. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. *Ann Oncol* 1995;6:805–810.
  63. Marty M, Kleisbauer JP, Fournel P, et al. Is navoban (tropisetron) as effective as zofran (ondansetron) in cisplatin-induced emesis? *Anti-Cancer Drugs* 1995;6(Suppl 1):S15–21.
  64. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. *J Clin Oncol* 1995;13:1242–1248.
  65. Stewart A, McQuade B, Cronje JDE, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in outpatients: a multi-centre, double-blind, double dummy, randomised, parallel-group study. *Oncology* 1995;52:202–210.
  66. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the antiemetic efficacy of two

## Antiemesis

- intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. *Eur J Cancer* 1996;32A:807–813.
67. Fauser AA, Duclos B, Chemaissani A, et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. *Eur J Cancer* 1996;32A:1523–1529.
  68. Hesketh PJ, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. *J Clin Oncol* 1996;14:2242–2249.
  69. Leonardi V, Iannitto E, Meli M, Palmeri S. Ondansetron vs granisetron in the control of chemotherapy-induced acute emesis: a multicenter randomized trial. *Oncology Rep* 1996;3:919–923.
  70. Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron, and evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. *J Clin Oncol* 1997;15:2966–2973.
  71. Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT<sub>3</sub>-receptor antagonists for acute chemotherapy-induced emesis. *Support Care Cancer* 2007;15:1023–1033.
  72. Huang JQ, Zheng GF, Deuson R, et al. Do 5-hydroxytryptamine<sub>3</sub> receptor antagonists (5-HT<sub>3</sub>) improve the antiemetic effect of dexamethasone for preventing delayed chemotherapy-induced nausea and vomiting (CINV)? A meta-analysis of randomized controlled trials [Abstract]. *J Clin Oncol* 2004;22:Abstract 6037.
  73. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. *Cancer* 2003;97:2290–2300.
  74. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. *J Clin Oncol* 2003;21:4112–4119.
  75. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials. *Eur J Cancer* 2004;40:403–410.
  76. Warr DG, Eisenberg P, Hesketh PJ, et al. Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: a randomized double-blind trial in 866 patients [Abstract]. *J Clin Oncol* 2004;22:Abstract 8007.
  77. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. *J Clin Oncol* 2005;23:2822–2830.
  78. Gralla RJ, Warr DG, Carides AD, et al. Effect of aprepitant on antiemetic protection in patients receiving moderately emetogenic chemotherapy plus high-dose cisplatin: analysis of combined data from 2 phase III randomized clinical trials [abstract]. *J Clin Oncol* 2004;22:Abstract 8137.
  79. Tremont-Lukats IW, González-Barboteo J, Bruera E, et al. Meta-analysis of neurokinin-1 receptor antagonists (NK-1 RA) for chemotherapy-induced nausea and vomiting (CINV) [Abstract]. *J Clin Oncol* 2004;22:Abstract 8047.
  80. Grote T, Hajdenberg J, Cartmell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. *J Support Oncol* 2006;4:403–408.
  81. Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. *J Clin Pharmacol* 2004;44:215–223.
  82. Emend [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2003. Available at: <http://www.fda.gov/cder/foi/label/2008/021549s0151bl.pdf>. Accessed April 7, 2009.
  83. Wampler G. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. *Drugs* 1983;25:31–51.
  84. Gralla RJ, Braun TJ, Itri LM, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. *N Engl J Med* 1981;305:905–909.
  85. Gralla RJ, Tyson LB, Borden LA, et al. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. *Cancer Treat Rep* 1984;68:163–172.
  86. Bakowski MT. Advances in anti-emetic therapy. *Cancer Treat Rev* 1984;11:237–256.
  87. Grossman B, Lessen LS, Cohen P. Droperidol prevents nausea and vomiting from cisplatin (letter). *N Engl J Med* 1979;301:7.
  88. Aapro MS, Alberts DS. High dose dexamethasone for prevention of cisplatin-induced vomiting. *Cancer Chemother Pharmacol* 1981;7:11–14.
  89. Aapro MS, Plezia PM, Alberts DS, et al. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. *J Clin Oncol* 1984;2:466–471.
  90. Cassileth PA, Lusk EJ, Torri S, et al. Antiemetic efficacy of dexamethasone therapy in patients receiving chemotherapy. *Arch Intern Med* 1983;143:1347–1349.
  91. Kris MG, Gralla RJ, Clark RA, et al. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. *Cancer Treat Rep* 1985;69:1257–1262.
  92. Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metoclopramide plus dexamethasone: a double-blind, randomized trial. *Cancer* 1987;69:1353–1357.
  93. Herman TS, Einhorn LH, Jones SE. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. *N Engl J Med* 1979;200:1295–1297.
  94. Steele N, Gralla RJ, Braun DW, et al. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. *Cancer Treat Rep* 1980;64:219–224.
  95. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV) [Abstract]. *J Clin Oncol* 2004;22:Abstract 8046.
  96. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea

## Antiemesis

- and vomiting: a Hoosier Oncology Group study. *Support Care Cancer* 2005;13:529–534.
97. Srivastava M, Brito-Dellan N, Davis MP, et al. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. *J Pain Symptom Manage* 2003;25:578–582.
  98. Passik SD, Navari RM, Jung SH, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. *Cancer Invest* 2004;22:383–388.
  99. Passik SD, Kirsh KL, Theobald DE, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. *J Pain Symptom Manage* 2003;25:485–488.
  100. Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. *J Pain Symptom Manage* 2002;23:526–532.
  101. Morita T, Tei Y, Shishido H, et al. Olanzapine-induced delirium in a terminally ill cancer patient. *J Pain Symptom Manage* 2004;28:102–103.
  102. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. *Lancet Oncol* 2009;10:115–124.
  103. Geling O, Eichler H-G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. *J Clin Oncol* 2005;23:1289–1294.
  104. Massa E, Astaro G, Madeddu C, et al. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. *Crit Rev Oncol Hematol* 2009;70:83–91.
  105. Franzen L, Nyman J, Hagberg H, et al. A randomized placebo-controlled study with ondansetron in patients undergoing fractionated radiotherapy. *Ann Oncol* 1996;7:587–592.
  106. Wong RK, Paul N, Ding K, et al. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). *J Clin Oncol* 2006;24:3458–3464.
  107. Belkacemi Y, Ozsahim M, Pene F, et al. Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. *Int J Radiation Oncol Biol Phys* 1996;36:77–82.
  108. Okamoto S, Takahashi S, Tanosaki R, et al. Granisetron in the prevention of vomiting induced conditioning for stem cell transplantation: a prospective randomized study. *Bone Marrow Transplant* 1996;17:679–683.
  109. Ezzo J, Vickers A, Richardson MA, et al. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. *J Clin Oncol* 2005;23:7188–7198.
  110. Morrow GR, Morrell C. Behavioral treatment for the anticipating nausea and vomiting induced by cancer chemotherapy. *N Engl J Med* 1982;307:1476–1480.
  111. Redd WH, Andrykowski MA. Behavioral intervention in cancer treatment: controlling aversion reactions to chemotherapy. *J Consult Clin Psychol* 1982;50:1018–1029.
  112. Razavi D, Delvaux N, Farvacques C, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study of assessing the usefulness of alprazolam. *J Clin Oncol* 1993;11:1384–1390.
  113. Physicians' Desk Reference, 58<sup>th</sup> ed. Montvale, NJ: Thomson PDR; 2004. Available at <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5816#nmlm34068-7>. Accessed April 7, 2009.
  114. Ellebaek E, Herrstedt J. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. *Curr Opin Support Palliat Care* 2008;2:28–34.
  115. Einhorn LH, Rapoport B, Koeller J, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. *Support Care Cancer* 2005;13:112–116.
  116. Navari RM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. *J Natl Compr Canc Netw* 2007;5:51–59.
  117. Herrstedt J, Sigsgaard TC, Nielsen HA, et al. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. *Support Care Cancer* 2007;15:417–426.

## Antiemesis

Individual Disclosures of the NCCN Antiemesis Panel					
Panel Member	Clinical Research Support	Advisory Boards, Speakers Bureau, Expert Witness, or Consultant	Patent, Equity, or Royalty	Other	Date Completed
Debra K. Armstrong, RN	Morphotek Inc.; and Agensys	Agiotech Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Fresenius Medical Care AG; Genentech, Inc.; Morphotek Inc.; Agensys; OCl; and Oncotech	None	None	11/19/08
Sally Barbour, PharmD, BCOP	None	None	None	None	7/15/08
Michael J. Berger, PharmD, BCOP	None	None	None	None	7/11/08
Philip J. Bierman, MD	None	None	None	None	6/20/08
Bob Bradbury, BCPS	None	None	None	None	4/22/08
Georgiana Ellis, MD	MGI PHARMA, INC.	None	None	None	11/16/08
David S. Ettinger, MD	Abbott Laboratories; Amgen Inc.; ARIAD Pharmaceuticals, Inc.; BioNumerik Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Exelixis Inc.; Genentech, Inc.; ImClone Systems Incorporated; Merck & Co., Inc.; Morphotek Inc.; Novartis Pharmaceuticals Corporation; OSI Pharmaceuticals, Inc.; Pfizer Inc.; sanofi-aventis U.S.; Schering-Plough Corporation; and Taiho Pharmaceuticals Co., Ltd.	AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; and GlaxoSmithKline	None	Eli Lilly and Company; and Genentech, Inc.	9/2/08
Steve Kirkegaard, PharmD	None	Eisai Inc.	None	None	7/23/08
Dwight D. Kloth, PharmD, FCCP, BCOP	None	Amgen Inc.; GlaxoSmithKline; and MGI PHARMA, INC.	None	None	7/20/08
Mark G. Kris, MD	None	Astra Zeneca Pharmaceuticals LP	None	None	10/15/08
Dean Lim, MD	None	None	None	None	11/21/08
Michael Anne Markiewicz, PharmD	None	None	None	None	7/15/08
Lida Nabati, MD	None	None	None	None	7/23/08
Carli Nesheiwat, PharmD, BCOP	None	None	None	None	9/5/08
Hope S. Rugo, MD	None	None	None	None	12/26/08
Steven M. Sorscher, MD	None	None	None	None	7/23/08
Lisa Stucky-Marshall, RN, MS	None	None	None	None	7/9/08
Barbara Todaro, PharmD	None	None	None	None	7/23/08
Susan Urba, MD	MGI PHARMA, INC.	Merck & Co., Inc.; and MGI PHARMA, INC.	None	None	7/21/08

The NCCN guidelines staff have no conflicts to disclose.